December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

6.100 +0.230 (+3.92%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
From Coya Therapeutics, Inc.
Via Business Wire
Updated Lineup Announced for iAccess Alpha's Virtual Summer Investment Conference, June 24–25, 2025
Via ACCESS Newswire
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
Via ACCESS Newswire
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announce Positive Interim Result from Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
Via Get News
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
From Coya Therapeutics, Inc.
Via Business Wire
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
Enters into Agreement with Bradley L. Radoff and Michael Torok 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces $10.0 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
From Coya Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.